FindTrial
Sign In

Efficacy of lamivudine plus adefovir therapy or adefovir add on therapy for entecavir-resistant hepatitis B patients

Efficacy of lamivudine plus adefovir therapy or adefovir add on therapy for entecavir-resistant hepatitis B patients

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CRIS
Registry ID
KCT0000085
Enrollment
37
Registered
2011-01-24
Start date
2010-09-01
Completion date
Unknown
Last updated
2019-03-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

None listed

Sponsors

Ajou University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: ETV-refractory chronic hepatitis B patients

Exclusion criteria

Exclusion criteria: co-infections (hepatitis C virus or human immunodeficiency virus) or other concomitant liver disease such as alcoholic liver disease or autoimmune liver disease.

Design outcomes

Primary

MeasureTime frame
HBeAg seroconversion or HBeAg loss;HBV DNA negativity—

Secondary

MeasureTime frame
ALT normalization—

Countries

Korea, Republic of

Contacts

Public ContactSoon-sun Kim

Ajou University

Outcome results

None listed

Source: CRIS (via WHO ICTRP) · Data processed: Feb 4, 2026